<< back

Announcement 6th Januar 2025, update 16th April 2025

HDFTY – A Huntington’s disease study to repurpose FTY720 – funding aquisition
Funding organisations: We try to aquire funding from private and state organisations. Please send us your donation!
Proposed start of the study: 2025

Partners:
Prof. Jens Pahnke, M.D., Ph.D., University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo, Norway
Prof. Ramona Valante, M.D., University of Latvia, Faculy of Medicine and Life Sciences, Department of Neuromedicine and Neuroscience, Riga, Latvia
Prof. Tatyana Gurevich, M.D., National Huntington’s Disease Center at Sourasky Medical Center, Tel Aviv, Israel

Interested ? Pls send an Email to us !

Abstract:
Since a few years, we have investigated novel treatment options for Huntington’s disease based on our previous work on Alzheimer’s disease and ABC transporters.
Recently, we have discovered an effective treatment to modulate disease onset and disease progress (Wu et al. 2025) based on a known molecular signalling mechanism involving ceramides and sphingomyelin metabolism (S1PR1).
We have tested a drug used for Multiple sclerosis treatment, fingolimod – also known as FTY720, in a cross-over design study involving 128 mice until the age of 57 weeks.
We confirmed disease preventing effects in female mice and disease delaying effects in male mice.
We also determined the rescue of organ atrophy due to HD in the mice (testis, brain) and improvement of essential motor functions.

Keywords: Huntington’s disease; drug repurposing; neurodegenerative diseases; sphingomyelin signalling; Fingolimod; FTY720

Resources / Links:
A7HD project application to JPND 2024 – read more….